WO1988007870A1 - Procede de piegeage de substances biologiquement actives et son utilisation - Google Patents

Procede de piegeage de substances biologiquement actives et son utilisation Download PDF

Info

Publication number
WO1988007870A1
WO1988007870A1 PCT/SE1988/000183 SE8800183W WO8807870A1 WO 1988007870 A1 WO1988007870 A1 WO 1988007870A1 SE 8800183 W SE8800183 W SE 8800183W WO 8807870 A1 WO8807870 A1 WO 8807870A1
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
formulation according
polymer
substances
characterizedby
Prior art date
Application number
PCT/SE1988/000183
Other languages
English (en)
Inventor
Ulf SCHRÖDER
Catharina Lager
Original Assignee
Carbomatrix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbomatrix Ab filed Critical Carbomatrix Ab
Publication of WO1988007870A1 publication Critical patent/WO1988007870A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Abstract

Formulation pharmaceutique réalisée à partir d'une microsphère/particule préfabriquée, combinée avec un polymère pharmaceutiquement acceptable retardant la libération de la substance biologiquement active. L'utilisation de la formulation se rapportant à la substance biologiquement active est également divulguée.
PCT/SE1988/000183 1987-04-09 1988-04-11 Procede de piegeage de substances biologiquement actives et son utilisation WO1988007870A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8701479A SE8701479L (sv) 1987-04-09 1987-04-09 Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
SE8701479-1 1987-04-09

Publications (1)

Publication Number Publication Date
WO1988007870A1 true WO1988007870A1 (fr) 1988-10-20

Family

ID=20368147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1988/000183 WO1988007870A1 (fr) 1987-04-09 1988-04-11 Procede de piegeage de substances biologiquement actives et son utilisation

Country Status (2)

Country Link
SE (1) SE8701479L (fr)
WO (1) WO1988007870A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022318A1 (fr) * 1994-02-17 1995-08-24 Pankaj Modi Medicaments, vaccins et hormones incorpores dans des microspheres recouvertes de polylactides
EP0737472A1 (fr) * 1995-03-16 1996-10-16 LG Chemical Limited Formulation de vaccin pour une administration unique
EP0535937B1 (fr) * 1991-10-01 1997-06-11 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
FR2778336A1 (fr) * 1998-05-11 1999-11-12 Jean Pierre Perraud Implant injectable en sous-cutane et en sous-gingival resorbable a base de maltodextrine micro-encapsulee et resorbable en un temps determine
US6120787A (en) * 1995-10-19 2000-09-19 Biogram Ab Sustained release particles
EP0535387B2 (fr) † 1991-09-03 2001-10-04 Hoechst Aktiengesellschaft Particule échographique, préparation et application
WO2004094595A2 (fr) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Agents modifiés d'arni
WO2004094345A2 (fr) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Monomeres proteges
EP2216407A2 (fr) 2003-03-07 2010-08-11 Alnylam Pharmaceuticals, Inc. Compositions Therapeutiques
WO2011109427A2 (fr) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Amélioration de l'activité biologique de parni par modulation de son profil thermodynamique
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US9120031B2 (en) 2000-11-09 2015-09-01 Nektar Therapeutics Compositions of particulate coformulation
WO2016057693A1 (fr) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué
EP3141265A1 (fr) 2007-12-04 2017-03-15 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
EP3604533A1 (fr) 2008-04-11 2020-02-05 Arbutus Biopharma Corporation Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE328670B (fr) * 1962-12-19 1970-09-21 Smith Kline French Lab
SE413578B (sv) * 1973-03-28 1980-06-09 Benzon As Alfred Forfarande for framstellning av orala lekemedelspreparat med forlengda verkningstider
EP0026599A1 (fr) * 1979-09-12 1981-04-08 Eli Lilly And Company Copolymère de l'acide lactique et de l'acide glycolique et procédé pour sa préparation
WO1984000294A1 (fr) * 1982-07-09 1984-02-02 Ulf Schroeder Matrice d'hydrate de carbone cristallise pour des substances biologiquement actives, procede de preparation d'une telle matrice et son utilisation
EP0102265A2 (fr) * 1982-07-29 1984-03-07 The Stolle Research And Development Corporation Formulation injectable de microparticules à effet prolongé pour l'administration d'agents anti-inflammatoires
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
EP0147335A2 (fr) * 1984-01-02 1985-07-03 LABORATOIRES D'HYGIENE ET DE DIETETIQUE L.H.D. Société Anonyme dite: Matrice pharmaceutique inerte à base de polycaprolactone et procédé de préparation d'une forme galénique orale

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE328670B (fr) * 1962-12-19 1970-09-21 Smith Kline French Lab
SE413578B (sv) * 1973-03-28 1980-06-09 Benzon As Alfred Forfarande for framstellning av orala lekemedelspreparat med forlengda verkningstider
EP0026599A1 (fr) * 1979-09-12 1981-04-08 Eli Lilly And Company Copolymère de l'acide lactique et de l'acide glycolique et procédé pour sa préparation
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
WO1984000294A1 (fr) * 1982-07-09 1984-02-02 Ulf Schroeder Matrice d'hydrate de carbone cristallise pour des substances biologiquement actives, procede de preparation d'une telle matrice et son utilisation
EP0102265A2 (fr) * 1982-07-29 1984-03-07 The Stolle Research And Development Corporation Formulation injectable de microparticules à effet prolongé pour l'administration d'agents anti-inflammatoires
EP0147335A2 (fr) * 1984-01-02 1985-07-03 LABORATOIRES D'HYGIENE ET DE DIETETIQUE L.H.D. Société Anonyme dite: Matrice pharmaceutique inerte à base de polycaprolactone et procédé de préparation d'une forme galénique orale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. 9, No. 180 (C-293); & JP,A,60 048 923, published 16 March 1985. *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535387B2 (fr) † 1991-09-03 2001-10-04 Hoechst Aktiengesellschaft Particule échographique, préparation et application
EP0535937B1 (fr) * 1991-10-01 1997-06-11 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
WO1995022318A1 (fr) * 1994-02-17 1995-08-24 Pankaj Modi Medicaments, vaccins et hormones incorpores dans des microspheres recouvertes de polylactides
EP0737472A1 (fr) * 1995-03-16 1996-10-16 LG Chemical Limited Formulation de vaccin pour une administration unique
US5753234A (en) * 1995-03-16 1998-05-19 Lg Chemical Ltd. Single-shot vaccine formulation
US6120787A (en) * 1995-10-19 2000-09-19 Biogram Ab Sustained release particles
US6572893B2 (en) 1996-12-31 2003-06-03 Inhale Therapeutic Systems, Inc. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US5985248A (en) * 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6365190B1 (en) 1996-12-31 2002-04-02 Inhale Therapeutic Systems, Inc. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
FR2778336A1 (fr) * 1998-05-11 1999-11-12 Jean Pierre Perraud Implant injectable en sous-cutane et en sous-gingival resorbable a base de maltodextrine micro-encapsulee et resorbable en un temps determine
US10798955B2 (en) 2000-11-09 2020-10-13 Nektar Therapeutics Compositions of particulate coformulation
US9120031B2 (en) 2000-11-09 2015-09-01 Nektar Therapeutics Compositions of particulate coformulation
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
EP2216407A2 (fr) 2003-03-07 2010-08-11 Alnylam Pharmaceuticals, Inc. Compositions Therapeutiques
EP2239329A1 (fr) 2003-03-07 2010-10-13 Alnylam Pharmaceuticals, Inc. Compositions thérapeutiques
EP3450559A1 (fr) 2003-03-07 2019-03-06 Alnylam Pharmaceuticals, Inc. Compositions thérapeutiques
EP2660322A2 (fr) 2003-04-17 2013-11-06 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
WO2004094345A2 (fr) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Monomeres proteges
WO2004094595A2 (fr) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Agents modifiés d'arni
EP2669377A2 (fr) 2003-04-17 2013-12-04 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
EP2666858A1 (fr) 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
EP2664672A1 (fr) 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
EP3705125A1 (fr) 2007-12-04 2020-09-09 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés en tant qu'agents d'administration pour des oligonucléotides
EP3141265A1 (fr) 2007-12-04 2017-03-15 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
EP4223299A2 (fr) 2007-12-04 2023-08-09 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
EP4321177A2 (fr) 2007-12-04 2024-02-14 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
EP3604533A1 (fr) 2008-04-11 2020-02-05 Arbutus Biopharma Corporation Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques
WO2011109427A2 (fr) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Amélioration de l'activité biologique de parni par modulation de son profil thermodynamique
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2016057693A1 (fr) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué

Also Published As

Publication number Publication date
SE8701479L (sv) 1988-10-10
SE8701479D0 (sv) 1987-04-09

Similar Documents

Publication Publication Date Title
WO1988007870A1 (fr) Procede de piegeage de substances biologiquement actives et son utilisation
US5384124A (en) Solid porous unitary form comprising micro-particles and/or nano-particles, and its preparation
Kas Chitosan: properties, preparations and application to microparticulate systems
US4794001A (en) Formulations providing three distinct releases
EP1094790B9 (fr) Preparation pharmaceutique a liberation prolongee de phenytoine sodium
US4904476A (en) Formulations providing three distinct releases
EP0202051B1 (fr) Compositions thérapeutiques pour administration orale
EP0239361B1 (fr) Préparation pharmaceutique à libération prolongée
US5238686A (en) Sustained-release pharmaceutical preparation
JP4107678B2 (ja) 制御放出製剤
US4263273A (en) Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
JP5175017B2 (ja) 有効成分の経口吸収を改善するための粒子状担体
FI77573C (fi) Ny konsistens.
US9839617B2 (en) Nanoencapsulation of hydrophilic active compounds
US20060115525A1 (en) Pharmaceutical compositions
KR20050005438A (ko) 활성 성분 마이크로캡슐의 경구 현탁액
JPH07145045A (ja) 経口投与用薬物の微細カプセル化方法
SE455836B (sv) Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
CN106421800A (zh) 丝素蛋白改性凹坑结构乳酸基聚合物载药微球及制备方法
JP2006527265A (ja) レクチン含有天然物の腸溶性コーティング用組成物
WO1989003674A1 (fr) Microspheres, procede de production des microspheres et leur utilisation
CS396391A3 (en) Theophyline-containing retarded preparation
US20050079222A1 (en) Production of nanoparticles from methyl vinyl ether and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases
EP2001444A2 (fr) Formulations enrobées pour tolterodine
WO1992001443A1 (fr) Compositions contenant des matrices de microparticules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE